Sort
8,912 grants matching “sars cov 2”
Systems Immunogenetics of Influenza Virus Infection in the Collaborative Cross
$564,671Mark T Heise · Univ Of North Carolina Chapel Hill · U19 · FY2020 · AI
Modeling the Coupled Dynamics of COVID-19 Transmission and Protective Behaviors
$563,858Raffaele Vardavas · Rand Corporation · R01 · FY2023 · AI
Systems Immunogenetics of Influenza Virus Infection in the Collaborative Cross
$563,507Mark T Heise · Univ Of North Carolina Chapel Hill · U19 · FY2020 · AI
Systems Immunogenetics of Biodefense and Emerging Pathogens in the Collaborative Cross
$563,507Ralph S Baric · Univ Of North Carolina Chapel Hill · U19 · FY2020 · AI
Scramblases for protein glycosylation
$563,378Anant K Menon · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · GM
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasma
$562,991Gordon R. Bernard · Vanderbilt University Medical Center · UL1 · FY2020 · TR
Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis
$562,793Alfred Ayala · Rhode Island Hospital · R35 · FY2025 · GM
Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis
$562,793Alfred Ayala · Rhode Island Hospital · R35 · FY2024 · GM
Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis
$562,793Alfred Ayala · Rhode Island Hospital · R35 · FY2023 · GM
Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis
$562,793Alfred Ayala · Rhode Island Hospital · R35 · FY2022 · GM
A novel role for E2fs: E2f7 and E2f8 control motile ciliogenesis
$562,781Ute M Moll · State University New York Stony Brook · R01 · FY2024 · HL
Covid 19 cytokine storm
$562,646Sumant Singh Chugh · Rush University Medical Center · R01 · FY2021 · DK
Statistical adjustments of sample representation in community-level estimates of COVID-19 transmission and immunity
$562,066Yajuan Si · University Of Michigan At Ann Arbor · U01 · FY2023 · MD
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism
$561,819Steffanie A Strathdee · University Of California, San Diego · R01 · FY2021 · DA
Modeling the Coupled Dynamics of COVID-19 Transmission and Protective Behaviors
$561,498Raffaele Vardavas · Rand Corporation · R01 · FY2024 · AI
Mechanism of Immune Dysfunction and Morbid Outcomes in Response to Shock/Sepsis
$561,402Alfred Ayala · Rhode Island Hospital · R35 · FY2021 · GM
TOP3B as host factor and drug target
$561,360Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)
$561,279Monica Kraft · University Of Arizona · U19 · FY2020 · AI
Clinical Core
$561,279Monica Kraft · University Of Arizona · U19 · FY2020 · AI
Community Activation to TrAnsform Local sYSTems (CATALYST)
$561,185Alana M.w. Lebron · University Of California-Irvine · U01 · FY2023 · MD
Design of fusion inhibitors to block measles host-to-host infection
$561,162Matteo Porotto · Columbia University Health Sciences · R56 · FY2021 · AI
Impact of SARS-CoV-2 on the cerebrovasculature as a risk factor for VCID: Role of Wnt/beta-catenin
$561,155Sarah Elizabeth Lutz · University Of Illinois At Chicago · R56 · FY2024 · NS
Hypertension augmented COVID-19 through renin-induced internalization of platelet-ACE2 / SARS-Cov-2 complexes
$560,893Thomas M McIntyre · Cleveland Clinic Lerner Com-Cwru · R01 · FY2024 · HL
Determinants of Coronavirus Fidelity in Replication and Pathogenesis
$560,000Mark R Denison · Vanderbilt University · R01 · FY2013 · AI
The effect of HIV on SARS-CoV-2 transmission and emergence of variants of concern
$559,720Sanghyuk Sam Shin · University Of California-Irvine · R01 · FY2023 · AI